Login to Your Account



Sophiris wows Street with prostate cancer data

By Michael Fitzhugh
Staff Writer

Saturday, June 11, 2016

Sophiris Bio Inc.'s shares (NASDAQ:SPHS) rose 69.2 percent to a $1.98 close on Friday after publishing data showing that a single injection of PRX302 (topsalysin) durably destroyed localized prostate cancer tumor cells in half of the 18 men enrolled in an open-label phase IIa study.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription